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AUC0–∞ values were obtained, respectively, for patients with psoriasis 
and healthy volunteers: (S)-(+)-VLX, 729.7 vs 647.9 ng·h/mL; (R)-(-)-
VLX, 532.0 vs 327.6 ng·h/mL; (S)-(+)-ODV, 2742.7 vs 2463.1 ng·h/
mL; (R)-(-)-ODV, 2977.0 vs 2603.6 ng·h/mL; (S)-(+)-NDV, 281.7 vs 
60.8 ng·h/mL; (R)-(-)-NDV, 507.2 vs 192.3 ng·h/mL; (S)-(+)-DDV, 
758.6 vs 585.5 ng·h/mL; and (R)-(-)-DDV, 563.5 vs 482.9 ng·h/mL.
Conclusion: Psoriasis did not alter the kinetic disposition and metab-
olism of venlafaxine enantiomers following a single oral administra-
tion of the racemic drug.
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Introduction: Critically ill patients may display altered pharmacoki-
netic parameters. Therapeutic drug monitoring (TDM) is essential 
to optimize the use of antibiotics in intensive care units. Many TDM 
assessments may be inappropriate as a result of improper interpreta-
tion or collection timing. We assessed the practice of TDM of vanco-
mycin and aminoglycosides in an adult intensive care unit.
Patients (or Materials) and Methods: We performed a retrospective 
analysis of all vancomycin and aminoglycosides plasma level deter-
minations performed between January 1, 2011, and December 31, 
2011, in adult patients admitted in the intensive care unit of Geneva 
University Hospitals, Switzerland.
Results: A total of 845 antibiotic plasma levels were performed 
in 193 patients, among which 773 levels could be interpreted. The 
majority of TDM were related to vancomycin (87%), while amino-
glycoside TDM were less frequent (13%). For intermittent vanco-
mycin, the dosage was not changed in 27% of high through levels 
and 23% of low through levels. A dosage increase was observed in 
only 22% of low through levels. Moreover, about one half of the 
samples were drawn too early. For continuous vancomycin, dosage 
was not changed in 17% of high plasma levels and 33% of low levels. 
A dosage increase was observed in only 30% of low levels. About 
60% of the samples were drawn too early. For aminoglycosides, the 
dosage was not changed in 20 to 30% of the cases when high through 
levels were measured. As for vancomycin, samples were frequently 
drawn too early.
Conclusion: Our results show that the practice of TDM of vanco-
mycin and aminoglycosides could be improved. Too high or too low 
levels did not systematically result in dosage changes and samples 
were frequently drawn too early.
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Introduction: In critically ill patients with hospital-acquired pneu-
monia, pathophysiologic changes alter the pharmacokinetics of 
antibiotics. Imipenem exhibits primarily time-dependent killing. Its 
administration by prolonging the intermittent infusion may increase 
time with serum concentrations above the minimum inhibitory con-
centration of the suspected pathogens (t > MIC).
Patients (or Materials) and Methods: Inclusion criteria were hos-
pital-acquired pneumonia, treatment by imipenem/cilastatin, and 
expected continuation of mechanic ventilation for at least 48 hours 
from the recruitment into the trial. Enrolled patients were randomly 
divided into either bolus group (to receive 1-g imipenem over 30 
minutes every 8 hours) or extended group (0.5 g administered over 
3 hours every 6 hours). Imipenem plasma concentrations were deter-
mined by reversed-phase HPLC during the second day of imipenem 
treatment. Pharmacokinetic data were determined using a 1-compart-
ment model. The target pharmacokinetic/pharmacodynamic param-
eter, percentage of dosing interval in which plasma concentration of 
imipenem exceeded 4 times the minimum inhibitory concentration 
(%t > 4 × MIC), was assessed using individual concentration–time 
curves for MIC of 0.5, 1, and 2 mg/L. Kolmogorov-Smirnov test was 
used to confirm normal distribution of data, which were then tested 
by unpaired t test.
Results: Twenty-two patients entered this study. Patients in both 
groups were matched with regard to other demographic data, renal 
functions, and severity of illness. The parameter % t > 4 × MIC was 
comparable in both groups for MIC of 0.5 mg/L, ranging from 74% 
to 100% in bolus group and from 55% to 100% in extended group. 
For MIC of 1 mg/L, the difference in both groups was not statistically 
significant, ranging from 59% to 100% in bolus group and from 
31% to 100% in extended group. However, in the extended group, 
in 2 patients (20%) imipenem concentration in plasma did not remain 
above 4 × MIC for 40 % of the dosing interval. All patients in the 
bolus group achieved the PK/PD target for MIC of 2 mg/L. In the 
extended group, majority of the patients did not achieve this target. 
On the other hand, imipenem plasma concentration was above 4 × 
MIC of 2 mg/L for more than 90% of the dosing interval in 1 patient 
in extended group.
Conclusion: In artificially ventilated patients with hospital-acquired 
pneumonia, prolonged infusion of imipenem/cilastatin to 3 hours 
(with reduced total daily dose) does not lead to an improvement of 
the main tested PK/PD parameter - time upon the 4 times suspected 
pathogen’s MIC.
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Introduction: Darunavir (DRV), a protease inhibitor, potently sup-
presses the replication of wild-type and drug-resistant HIV-1, but 
its clinical efficacy varies greatly among individuals. Recently, the 
importance of the concentrations of DRV in blood cells, the site of 
action for DRV, has been focused. In this study, we assessed the influ-
ence of plasma and intracellular concentration of DRV on its clinical 
efficacy. The factors acting for the intracellular concentration of DRV 
is also investigated.
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Patients (or Materials) and Methods: Patients treated with DRV for 
HIV infection were enrolled in this study. Efficacy of drug therapy 
was evaluated by relative change of copy number of HIV in blood, 
and the blood samples were taken when the relative copy number of 
< 200 copies/mL. The concentrations of DRV in plasma and PBMC 
were analyzed using HPLC-fluorescence detection method. Then, in 
vitro uptake study using human leukemia cell line, MOLT-4, was 
performed. The intracellular concentrations of DRV were measured 
after exposure to DRV (3.0 μ g/mL in medium) or the combination 
of DRV and ritnavir (RTV) (3.0 and 1.0 μ g/mL in medium, respec-
tively) for 2 hours.
Results: The effective concentrations of DRV in plasma showed 
great variation of 0.88 to 5.57 μ g/mL, while the concentrations 
in PBMC were maintained within a relatively-narrow range 12.9–
28.7ng/106 cells. In in vitro study, RTV, a P-gp inhibitor, significantly 
increase the intracellular concentration of DRV (10.0 vs 15.9 ng/106 
cells).
Conclusion: Our results suggested that the concentration of DRV 
in PBMC could be better indicator for clinical efficacy of DRV com-
pared with that in plasma. In in vitro study, we found that RTV could 
promote the intracellular accumulation of DRV, and it was thought 
to be due to the P-gp inhibitory activity of RTV. Those results mean 
that coadministration of RTV have possibility to increase intracel-
lular concentration of DRV and result to sufficient clinical efficacy of 
DRV regardless the concentration of DRV in plasma.
Disclosure of Interest: None declared.
PP200—MeTabolic Process of 
Voriconazole To iTs n-oxiDe is saTurable 
in clinical Dose range
T. Yamada*; Y. Mino; T. Yagi; T. Naito; and J. Kawakami
Hospital Pharmacy, Hamamatsu University School of Medicine, 
Hamamatsu, Japan
Introduction: Triazole antifungal agent voriconazole (VRCZ) 
has a nonlinear pharmacokinetics. VRCZ is extensively metabo-
lized hepatically to major inactive metabolites VRCZ N-oxide 
(VNO). Few clinical reports revealed the influence of VNO on the 
metabolic process of VRCZ. The present study aimed to evaluate 
metabolic process of VRCZ in patients taking plasma concentra-
tion of VNO.
Patients (or Materials) and Methods: Fifty-eight Japanese patients 
receiving oral or intravenous VRCZ for prophylaxis or fungal infec-
tions at Hamamatsu University Hospital were included in the study. 
Predose plasma concentrations of VRCZ and VNO were moni-
tored at day 5 or later. The relationships between plasma exposure 
parameters of VRCZ and VNO were evaluated. CYP2C19 genetic 
polymorphism (G636A and G681A on exon 4 and exon 5) were 
determined using PCR-RFLP method for assessing the influence of 
major metabolic enzyme of VRCZ.
Results: A large interindividual variation was observed in the plasma 
concentrations of VRCZ and VNO. Dose-normalized VRCZ con-
centration had a strong correlation with VRCZ concentration and a 
straight line passing through nearby the origin of the coordinates was 
obtained. No significant correlation between the plasma concentra-
tions of VRCZ and VNO was observed. Plasma concentration ratio 
of VRCZ to VNO (VRCZ/VNO) was strongly correlated with VRCZ 
concentration. No significant difference was observed in the plasma 
concentrations of VRCZ and VNO and VRCZ/VNO between the 
CYP2C19 genotypes.
Conclusion: Metabolic process of VRCZ to VNO is saturable in 
clinical dose range. Our findings indicated that nonlinear pharma-
cokinetics of VRCZ depends on its metabolic saturation
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Introduction: Retigabine (RTG)/ezogabine, N-[2-amino-4(4-
fluorobenzylamino)-phenyl] carbamic acid ethyl ester, is a novel 
antiepileptic compound. In 2011, RTG was approved by the FDA 
and European Commission as adjunctive treatment for partial onset 
seizures in adults aged ≥ 18 years. The global pivotal studies did not 
include Asian countries. The purpose of this study was to character-
ize the pharmacokinetics (PK) of single 50, 100, 200, and 400-mg 
doses of RTG and N-acetyl metabolites of RTG (NAMR) in healthy 
Taiwanese subjects.
Patients (or Materials) and Methods: Sixteen subjects were rand-
omized to the study (ANE116798, NCT01462669), which comprised 
a screening visit, 4 treatment periods, and a follow-up visit. The fol-
lowing PK parameters were determined for RTG and NAMR: Cmax, 
AUC0-inf, Tmax, and t½. Safety and tolerability were measured 
using adverse event (AE) reports, vital signs, electrocardiograms, clin-
ical laboratory measurements and Columbia Suicide Severity Rating 
Scale. Dose proportionality of RTG was assessed by fitting AUC0–inf 
and Cmax to a power model. A point estimate and 90% CI for the 
slope of the regression line obtained by regressing log(PK parameter) 
on log(dose) was calculated. As a secondary analysis, an analysis 
of variance was performed using loge-transformed dose-normalized 
AUC0–inf and Cmax by including periods and treatments as fixed 
effects and subjects as a random effect. All doses were compared with 
the 50 mg reference dose.
Results: Safety: No subject was withdrawn from the study owing to 
AEs and no serious AEs were reported. AEs reported most frequently 
in this population were somnolence, dizziness, and nausea, and the 
incidence of AEs increased with RTG dose. PK: Cmax value increases 
were approximately dose proportional from 50 to 100 mg, but less 
than dose proportional at 200 and 400 mg. AUC0–inf appeared 
to increase more than dose proportionally between 50 mg and the 
higher doses of 100, 200, and 400 mg. This was believed to be due 
to an underprediction of t½ at the 50-mg dose. AUC0–8, which 
represents the dosing interval of RTG with a 3-times-daily dosing 
regimen, was added as a post hoc PK parameter, since this truncated 
AUC is not confounded by determination of t½. AUC0–8 increased 
proportionally across the range of 50 to 400 mg.
Conclusion: Single oral doses of RTG (50–400 mg) were generally 
well tolerated in Taiwanese subjects. The PK parameters for RTG 
and NAMR in the current study in Taiwanese subjects are consistent 
with single-dose PK parameters obtained at these doses in healthy 
Western subjects.
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Introduction: Cachexia decreases CYP3A metabolism of oxycodone, 
while its influence on CYP2D6 metabolism remains to be clarified in 
